After securing Medicare reimbursement for its pacemaker-like heart failure (HF) implant, Impulse Dynamics has raised more ...
An Institute for Value-Based Medicine ® event held in New Haven, Connecticut, on October 30, 2025, brought together a diverse ...
Once largely a diagnosis of exclusion, new tools and treatments are unraveling some of the mysteries surrounding heart failure with preserved ejection fraction.
After lagging the market over the past couple of years, Merck (NYSE: MRK) has experienced a slight rebound in the last month, ...
A large Scandinavian study reopens the debate on beta-blockers after myocardial infarction, revealing selective benefits.
Researchers sought to assess clinical outcomes, prevalence, and 1-year outcomes associated with polypharmacy in patients with heart failure.
Background Dyspnoea and reduced exercise capacity are common features in hypertrophic cardiomyopathy (HCM) without left ...
This case report describes a woman in her late 50s with reversible pulmonary hypertension (PH) due to scurvy, a rare vitamin ...
Panelists considered the technology relatively safe but weren’t swayed by the “statistical gymnastics” needed to find a ...
The outside advisors analyzed the results of the RELIEVE-HF pivotal trial, which randomized 508 patients to either receive ...
An FDA advisory panel unanimously agreed that Johnson & Johnson MedTech's V-Wave Ventura interatrial shunt's risks outweigh ...
Zacks Investment Research on MSN
Why is Cytokinetics (CYTK) up 10.4% since last earnings report?
A month has gone by since the last earnings report for Cytokinetics (CYTK). Shares have added about 10.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback